Eupraxia Pharmaceuticals (EPRX) Competitors $3.81 -0.09 (-2.31%) Closing price 05/21/2025 03:56 PM EasternExtended Trading$3.97 +0.16 (+4.17%) As of 05/21/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. KURA, STOK, VALN, TYRA, ETON, OPT, RLAY, RGNX, AMLX, and UPBShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Kura Oncology (KURA), Stoke Therapeutics (STOK), Valneva (VALN), Tyra Biosciences (TYRA), Eton Pharmaceuticals (ETON), Opthea (OPT), Relay Therapeutics (RLAY), REGENXBIO (RGNX), Amylyx Pharmaceuticals (AMLX), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Kura Oncology Stoke Therapeutics Valneva Tyra Biosciences Eton Pharmaceuticals Opthea Relay Therapeutics REGENXBIO Amylyx Pharmaceuticals Upstream Bio Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Which has better earnings and valuation, EPRX or KURA? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Kura Oncology. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.76-5.01Kura Oncology$67.99M7.89-$152.63M-$2.10-2.95 Is EPRX or KURA more profitable? Kura Oncology's return on equity of -44.09% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -219.64% -96.00% Kura Oncology N/A -44.09%-39.57% Do analysts rate EPRX or KURA? Eupraxia Pharmaceuticals currently has a consensus price target of $10.50, suggesting a potential upside of 175.59%. Kura Oncology has a consensus price target of $24.50, suggesting a potential upside of 295.16%. Given Kura Oncology's higher probable upside, analysts clearly believe Kura Oncology is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.93 Does the MarketBeat Community favor EPRX or KURA? Kura Oncology received 436 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 69.73% of users gave Kura Oncology an outperform vote. CompanyUnderperformOutperformEupraxia PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo VotesKura OncologyOutperform Votes44069.73% Underperform Votes19130.27% Does the media prefer EPRX or KURA? In the previous week, Kura Oncology had 18 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 18 mentions for Kura Oncology and 0 mentions for Eupraxia Pharmaceuticals. Kura Oncology's average media sentiment score of 0.53 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media. Company Overall Sentiment Eupraxia Pharmaceuticals Neutral Kura Oncology Positive SummaryKura Oncology beats Eupraxia Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$136.59M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-5.298.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book127.006.466.794.50Net Income-$28.22M$143.98M$3.23B$248.18M7 Day Performance0.26%2.03%1.53%0.20%1 Month Performance-1.04%4.11%10.05%12.37%1 Year Performance29.15%-2.87%16.71%7.04% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.2038 of 5 stars$3.81-2.3%$10.50+175.6%+32.3%$136.59MN/A-5.2929Gap UpKURAKura Oncology4.3075 of 5 stars$6.38+2.2%$24.50+284.0%-72.0%$552.35M$67.99M-2.70130News CoverageAnalyst ForecastAnalyst RevisionSTOKStoke Therapeutics3.4811 of 5 stars$10.05+2.2%$23.20+130.8%-38.2%$548.70M$190.91M-4.79100Positive NewsAnalyst RevisionGap UpVALNValneva2.102 of 5 stars$6.41+1.0%$15.50+142.0%-22.2%$535.69M$186.06M-49.27700TYRATyra Biosciences1.6737 of 5 stars$9.98+3.1%$30.83+209.0%-47.1%$529.84MN/A-6.2020News CoveragePositive NewsAnalyst ForecastAnalyst RevisionETONEton Pharmaceuticals2.3894 of 5 stars$19.60+0.2%$29.00+48.0%+463.8%$525.63M$48.33M-89.0920Positive NewsAnalyst RevisionOPTOpthea0.671 of 5 stars$3.41+7.2%$1.33-60.9%+1.8%$524.84M$87,666.000.008Gap UpRLAYRelay Therapeutics3.3081 of 5 stars$3.05+4.1%$17.67+479.2%-62.2%$522.91M$7.68M-1.17330RGNXREGENXBIO4.2715 of 5 stars$10.00+2.1%$31.63+216.3%-37.1%$501.60M$156.72M-1.99370Analyst RevisionAMLXAmylyx Pharmaceuticals3.4624 of 5 stars$5.52+3.0%$9.83+78.1%+201.7%$492.06M$-1,272,000.00-1.45200UPBUpstream Bio2.0909 of 5 stars$9.13+0.9%$56.50+518.8%N/A$491.14M$2.30M0.0038News Coverage Related Companies and Tools Related Companies Kura Oncology Competitors Stoke Therapeutics Competitors Valneva Competitors Tyra Biosciences Competitors Eton Pharmaceuticals Competitors Opthea Competitors Relay Therapeutics Competitors REGENXBIO Competitors Amylyx Pharmaceuticals Competitors Upstream Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EPRX Stock Free EPRX Stock Alerts